Prelude Therapeutics
Clinical trials sponsored by Prelude Therapeutics, explained in plain language.
-
Promising combo for rare cancer mutation stalls as study ends early
Disease control TerminatedThis early-phase study tested a new drug called PRT3789 combined with the immunotherapy pembrolizumab (Keytruda) in people with advanced solid tumors that have a SMARCA4 gene mutation. The goal was to see if the combination was safe and could shrink tumors. However, the study was…
Phase: PHASE2 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Experimental cancer pill targets Hard-to-Treat tumors
Disease control TerminatedThis early-stage study tested an experimental oral drug called PRT7732 in people with advanced solid tumors that have a specific genetic mutation (SMARCA4). The main goals were to check safety, find the right dose, and see if the drug could shrink tumors. The study was terminated…
Phase: PHASE1 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC